Greg is Chief Medical and Information Officer at PRA Health Sciences, a leading pharmaceutical service, healthcare data and contract research provider. Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals, founder and President of Elipdera Therapeutics at Moderna, and had leadership roles at McKinsey & Co., Quintiles, Inc., Proteostasis, Amicus Therapeutics, Domain Associates and Medtronic Neurological. He was co-founder of Immunome Therapeutics. Greg has degrees from Harvard Business School, Yale School of Medicine, Columbia University, and Boston College. He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. He is on the advisory boards of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care.
- MBA, Harvard University, 2000
- MD, Yale University School of Medicine, 1995
Selected Working Papers
Medical Tourism, Neurosurgery and Singapore’s Largest Health System
Patients Left Behind: How Rare Dermatologic Conditions Missed the Orphan Drug Development Boom
Blockchain in healthcare
Yale SOM Cases
Licholai, G. (2016). Population Health Management at Atrius Health. Yale School of Management Case Study.
Licholai, G. (2016). Nomad Health and the disruption of physician staffing services. Yale School of Management Case Study.
Licholai, G. (2017). Everlywell and access to lab testing. Yale School of Management Case Study. (In press)
Licholai, G. (2016). Cobalt and the rise of digital behavioral healthcare. Yale School of
Management Case Study. (In press)
Licholai, G. (2016). CRISPR Therapeutics and Editing the Human Genome. Yale School of Management Case Study. (In press)